Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $10.46 USD
Change Today +0.26 / 2.55%
Volume 406.3K
OSIR On Other Exchanges
As of 4:30 PM 11/24/15 All times are local (Market data is delayed by at least 15 minutes).

osiris therapeutics inc (OSIR) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/17/15 - $23.38
52 Week Low
11/17/15 - $9.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

osiris therapeutics inc (OSIR) Related Businessweek News

No Related Businessweek News Found

osiris therapeutics inc (OSIR) Details

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix, a cryopreserved placental membrane for treating hard-to-treat acute and chronic wounds, venous leg ulcers, and burns; BIO4, a bone allograft for use in all surgical applications, including spine, trauma, extremity, cranial, and foot and ankle surgery; and Cartiform, a viable chondral allograft that promotes articular cartilage repair to treat focal chondral defects. It markets and distributes its products directly to hospitals, clinics, and physician offices as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

211 Employees
Last Reported Date: 03/20/15
Founded in 1992

osiris therapeutics inc (OSIR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $510.0K
Chief Financial Officer
Total Annual Compensation: $27.6K
Chief Medical Officer
Total Annual Compensation: $28.6K
Vice President and General Manager of Wound C...
Total Annual Compensation: $328.2K
Compensation as of Fiscal Year 2014.

osiris therapeutics inc (OSIR) Key Developments

Bronstein, Gewirtz & Grossman, LLC Announces Filing of Class Action Lawsuit against Osiris Therapeutics, Inc. and Certain of its Present and Former Officers

Bronstein, Gewirtz & Grossman, LLC announced that a class action lawsuit has been filed against Osiris Therapeutics, Inc. and certain of its present and former officers. The class action filed in the United District Court for the District of Maryland is on behalf of a class consisting of all persons or entities who purchased Osiris securities between May 12, 2014 and November 16, 2015 inclusive. This class action seeks to recover damages against defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The complaint alleges as follows: throughout the class period defendants made materially false and misleading statements regarding the company's business, operational and financial information. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) the company overstated revenues from several contracts and failed to follow GAAP standards, fixing its financial statements only a year and half later and causing millions in losses to the company and investors; and (ii) as a result of the foregoing, Osiris's public statements were materially false and misleading at all relevant times. It is alleged that on November 16, 2015, Osiris surprised investors by disclosing that it has 'determined to correct the revenue recognition for three contracts which will result in a decrease in product revenues of $1.8 million in the first quarter of 2015, a decrease in product revenue of $1.0 million in the second quarter, an increase in product revenues of $0.8 million in the third quarter of 2015 and a decrease in product revenues of $1.1 million in 2014. Thus, three restatements were made related to distributor relationships, which completely removed about $3.1 million of sales and shifted about $3.9 million of sales between quarters. As a result of these errors, Osiris missed its revenue targets in three of the last four quarters.

Osiris Therapeutics, Inc. Presents at Brean Capital 2015 Life Sciences Summit, Nov-16-2015

Osiris Therapeutics, Inc. Presents at Brean Capital 2015 Life Sciences Summit, Nov-16-2015 . Venue: Millennium Broadway Hotel, New York, New York, United States. Speakers: Frank D. Czworka, Vice President and General Manager of Wound Care, Gregory Ivan Law, Chief Financial Officer, Lode Debrabandere, Chief Executive Officer, President and Director.

Osiris Therapeutics, Inc. announced delayed 10-Q filing

On 11/10/2015, Osiris Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OSIR:US $10.46 USD +0.26

OSIR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $3.38 USD -0.02
CryoLife Inc $10.75 USD +0.45
Derma Sciences Inc $4.18 USD -0.07
Mesoblast Ltd A$1.58 AUD -0.14
Vitrolife AB kr233.50 SEK -9.50
View Industry Companies

Industry Analysis


Industry Average

Valuation OSIR Industry Range
Price/Earnings 100.0x
Price/Sales 4.1x
Price/Book 4.4x
Price/Cash Flow 244.4x
TEV/Sales 3.6x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact OSIRIS THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at